Haemonetics
HAE
Haemonetics (HAE) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 27, 2026
- EPS actual
- $1.14
- EPS estimate
- $1.08
- EPS surprise
- +5.87%
- Revenue surprise
- +3.51%
- Revenue
- $339.4M
- Revenue estimate
- $327.9M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Aug 6, 2026 | $1.08 | $1.14 | +5.87% | $339.4M | SEC |
| Q4 2026 | May 7, 2026 | $1.27 | $1.29 | +1.37% | $346.4M | SEC |
| Q3 2026 | Feb 5, 2026 | $1.25 | $1.31 | +4.83% | $339.0M | SEC |
| Q2 2026 | Nov 6, 2025 | $1.11 | $1.27 | +14.44% | $327.3M | SEC |
| Q1 2026 | Aug 7, 2025 | $1.01 | $1.10 | +9.11% | $321.4M | SEC |
| Q4 2025 | May 8, 2025 | $1.22 | $1.24 | +1.65% | $330.6M | SEC |
| Q3 2025 | Feb 6, 2025 | $1.17 | $1.19 | +1.37% | $348.5M | SEC |
| Q2 2025 | Nov 7, 2024 | $1.07 | $1.12 | +4.36% | $345.5M | SEC |
| Q1 2025 | Aug 8, 2024 | $1.01 | $1.02 | +1.44% | $336.2M | SEC |
| Q4 2024 | May 9, 2024 | $0.89 | $0.90 | +0.92% | $343.3M | SEC |
| Q3 2024 | Feb 8, 2024 | $0.94 | $1.04 | +10.46% | $336.3M | SEC |
| Q2 2024 | Nov 2, 2023 | $0.89 | $0.99 | +11.51% | $318.2M | SEC |
| Q1 2024 | Aug 8, 2023 | $0.72 | $1.05 | +45.25% | $311.3M | SEC |
| Q4 2023 | May 11, 2023 | $0.70 | $0.77 | +9.33% | $304.4M | SEC |
| Q3 2023 | Feb 7, 2023 | $0.82 | $0.85 | +4.06% | $305.3M | SEC |
| Q2 2023 | Nov 7, 2022 | $0.67 | $0.83 | +23.18% | $297.5M | SEC |
| Q1 2023 | Aug 10, 2022 | $0.51 | $0.58 | +13.73% | $261.5M | SEC |
| Q4 2022 | May 10, 2022 | $0.60 | $0.65 | +8.24% | $265.0M | SEC |
| Q3 2022 | Feb 8, 2022 | $0.73 | $0.85 | +15.18% | $259.8M | SEC |
| Q2 2022 | Nov 9, 2021 | $0.61 | $0.60 | −0.96% | $239.9M | SEC |
Quarterly revenue
Frequently asked questions
When did Haemonetics (HAE) last report earnings?
Haemonetics last reported on Aug 6, 2026, covering fiscal Q1 2027.
Did HAE beat earnings estimates?
Yes. Haemonetics reported EPS of $1.14 for Q1 2027 against a $1.08 estimate — a 5.87% beat.
How much revenue did HAE report last quarter?
Haemonetics reported $339.4M in revenue for Q1 2027, against a consensus estimate of $327.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.